{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:46:12Z","timestamp":1793997972558,"version":"4.8.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The cumulative impact of baseline comorbidities on outcomes of chimeric antigen receptor T-cell (CAR-T) therapy is not well established. Therefore, we developed and validated a Cellular Therapy Comorbidity Index (CT-CI) to predict outcomes following CD19-directed CAR-T therapy for large B-cell lymphoma (LBCL). Patients aged 18 or older receiving commercial CAR-T therapy for LBCL during 2017 to 2020 were selected from the Center for International Blood and Marrow Transplant Research registry. Patients were randomly assigned to training or validation cohorts. Comorbidities given weighted scores comprised the CT-CI, which was then validated for overall survival (OS) prognostication. A total of 1916 patients from 97 medical centers were included, with a median age of 64 years (19-91 years). About 70% of patients had comorbidities, such as cardiac disease (12%); diabetes (14%); hepatic dysfunction (mild, 8%; moderate to severe, 2%); psychiatric disturbance (18%); and pulmonary dysfunction (moderate, 15%; severe, 12%). The CT-CI was calculated, stratified patients in 3 categories, and was associated with increased mortality. Patients with higher CT-CI scores had worse OS (CT-CI 1: hazard ratio [HR], 1.37 [95%\u2009confidence interval [CI], 1.16-1.62; P&amp;lt;\u2009.001]; CT-CI 2: HR, 1.49 [95%\u2009CI, 1.17-1.89; P = .001]; CT-CI\u2009\u2265\u20093: HR, 2.55 [95%\u2009CI, 1.90-3.42; P&amp;lt;\u2009.001]). Higher CT-CI scores predicted treatment-related mortality and relapse. There was no correlation between the CT-CI score and CAR-T\u2013related toxicities. The novel CT-CI score stratifies the effect of patient comorbidities on survival after CAR-T therapy and can be used for clinical decision-making and treatment selection in high-risk populations. However, comorbidities and fear of increased toxicity should not preclude patients from this effective therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015599","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T20:56:04Z","timestamp":1755204964000},"page":"217-227","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-4572","authenticated-orcid":false,"given":"Uri","family":"Greenbaum","sequence":"first","affiliation":[{"name":"1Department of Hematology, Soroka University Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"2Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Elsawy","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Department of Medicine, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1404-0575","authenticated-orcid":false,"given":"Soyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"4Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI"},{"name":"5Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5110-004X","authenticated-orcid":false,"given":"Amy","family":"Moskop","sequence":"additional","affiliation":[{"name":"5Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"},{"name":"6Division of Pediatric Hematology\/Oncology\/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitope","family":"Oloyede","sequence":"additional","affiliation":[{"name":"5Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-9812","authenticated-orcid":false,"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[{"name":"7Section of Hematologic Malignancies and Cellular Therapy, Division of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"8Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[{"name":"9Blood and Marrow Transplantation Program, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Bar","sequence":"additional","affiliation":[{"name":"10Division of Clinical Research, Fred Hutchinson Cancer Center and Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Barba","sequence":"additional","affiliation":[{"name":"11Hematology Department, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"},{"name":"12Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Beitinjaneh","sequence":"additional","affiliation":[{"name":"13Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Cashen","sequence":"additional","affiliation":[{"name":"14Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"15Division of Hematology\/Oncology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-9891","authenticated-orcid":false,"given":"Umar","family":"Farooq","sequence":"additional","affiliation":[{"name":"16Department of Internal Medicine, University of Iowa, Iowa City, IA"},{"name":"17Division of Hematology, Oncology and Blood & Marrow Transplantation, Holden Comprehensive Cancer, University of Iowa Hospitals and Clinics, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Foglesong","sequence":"additional","affiliation":[{"name":"18Pediatric Stem Cell Transplantation and Cellular Therapy Program, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[{"name":"19Division of Hematology, Houston Methodist Hospital and Neal Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5836-4497","authenticated-orcid":false,"given":"Peiman","family":"Hematti","sequence":"additional","affiliation":[{"name":"20Blood and Marrow Transplant Program & Cellular Therapy Program, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-935X","authenticated-orcid":false,"given":"LaQuisa C.","family":"Hill","sequence":"additional","affiliation":[{"name":"21Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children\u2019s Hospital and Houston Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-1257","authenticated-orcid":false,"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[{"name":"22Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"},{"name":"23Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[{"name":"24Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"25Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[{"name":"26Division of Hematology\/Oncology, Department of Internal Medicine, Icahn School of Medicine at Mt. Sinai, Tisch Cancer Institute, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"22Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7707-2331","authenticated-orcid":false,"given":"Premal D.","family":"Lulla","sequence":"additional","affiliation":[{"name":"21Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children\u2019s Hospital and Houston Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[{"name":"27Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mead","sequence":"additional","affiliation":[{"name":"28Department of Anesthesiology & Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4088-036X","authenticated-orcid":false,"given":"Alberto","family":"Mussetti","sequence":"additional","affiliation":[{"name":"29Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia-Hospitalet, Barcelona, Spain"},{"name":"30Department of Hematology, Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"22Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"},{"name":"27Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1669-0355","authenticated-orcid":false,"given":"Amanda L.","family":"Olson","sequence":"additional","affiliation":[{"name":"25Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pennisi","sequence":"additional","affiliation":[{"name":"31Department of Oncology and Hematology Service, Istituto Nazionale dei Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"32Department of Medicine, Weill Cornell Medical College, New York, NY"},{"name":"33Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Ramakrishnan","family":"Geethakumari","sequence":"additional","affiliation":[{"name":"7Section of Hematologic Malignancies and Cellular Therapy, Division of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0580","authenticated-orcid":false,"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[{"name":"34David and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[{"name":"5Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"},{"name":"35BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8032","authenticated-orcid":false,"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[{"name":"32Department of Medicine, Weill Cornell Medical College, New York, NY"},{"name":"36Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[{"name":"37Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6798-8709","authenticated-orcid":false,"given":"Margarida","family":"Magalhaes-Silverman","sequence":"additional","affiliation":[{"name":"17Division of Hematology, Oncology and Blood & Marrow Transplantation, Holden Comprehensive Cancer, University of Iowa Hospitals and Clinics, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Strouse","sequence":"additional","affiliation":[{"name":"17Division of Hematology, Oncology and Blood & Marrow Transplantation, Holden Comprehensive Cancer, University of Iowa Hospitals and Clinics, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[{"name":"38Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"39Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Vallurupalli","sequence":"additional","affiliation":[{"name":"40Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitsada","family":"Wudhikarn","sequence":"additional","affiliation":[{"name":"41Center of Excellence in Translational Hematology and Division of Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[{"name":"5Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"},{"name":"35BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"42Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5260-1981","authenticated-orcid":false,"given":"Mohamed","family":"Sorror","sequence":"additional","affiliation":[{"name":"38Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"39Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"1","key":"2026012009164209200_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"2026012009164209200_bib2","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"27","key":"2026012009164209200_bib3","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026012009164209200_bib4","first-page":"337","article-title":"The impact of comorbidity on cancer and its treatment","volume":"66","author":"Sarfati","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2026012009164209200_bib5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/CJI.0000000000000366","article-title":"Immunotherapy utilization among patients with metastatic NSCLC: impact of comorbidities","volume":"44","author":"Zhang","year":"2021","journal-title":"J Immunother"},{"key":"2026012009164209200_bib6","doi-asserted-by":"crossref","first-page":"e922576","DOI":"10.12659\/MSM.922576","article-title":"Effect of comorbidity on outcomes of patients with advanced non-small cell lung cancer undergoing anti-PD1 immunotherapy","volume":"26","author":"Zeng","year":"2020","journal-title":"Med Sci Monit"},{"key":"2026012009164209200_bib7","doi-asserted-by":"crossref","first-page":"980181","DOI":"10.3389\/fonc.2022.980181","article-title":"Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors. Original Research","volume":"12","author":"Young","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"2026012009164209200_bib8","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1200\/OP.21.00196","article-title":"Using geriatric assessment to guide conversations regarding comorbidities among older patients with advanced cancer","volume":"18","author":"Kleckner","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"2026012009164209200_bib9","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"21","key":"2026012009164209200_bib10","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2026012009164209200_bib11","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"15","key":"2026012009164209200_bib12","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","article-title":"How I assess comorbidities before hematopoietic cell transplantation","volume":"121","author":"Sorror","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2026012009164209200_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2026012009164209200_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2003-04-1311","article-title":"Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients","volume":"103","author":"Hogan","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2026012009164209200_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/10428194.2022.2148213","article-title":"Organ toxicities associated with chimeric antigen receptor T-cell therapy","volume":"64","author":"McGann","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2026012009164209200_bib16","doi-asserted-by":"crossref","first-page":"7224","DOI":"10.1182\/blood-2024-208557","article-title":"Exercise prehabilitation for older adults undergoing CAR-T: feasibility and preliminary outcomes from a single-arm pilot study","volume":"144","author":"Parker","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026012009164209200_bib17","first-page":"46","article-title":"Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis","volume":"27","author":"Kittai","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"2026012009164209200_bib18","doi-asserted-by":"crossref","first-page":"877477","DOI":"10.3389\/fimmu.2022.877477","article-title":"EASIX and severe endothelial complications after CD19-directed CAR-T cell therapy-A cohort study","volume":"13","author":"Korell","year":"2022","journal-title":"Front Immunol"},{"issue":"14","key":"2026012009164209200_bib19","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T\u2013related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"issue":"14","key":"2026012009164209200_bib20","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1182\/bloodadvances.2022009309","article-title":"A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma","volume":"7","author":"Shouse","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2026012009164209200_bib21","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.2001.19.4.1147","article-title":"Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base","volume":"19","author":"Yancik","year":"2001","journal-title":"J Clin Oncol"},{"issue":"26","key":"2026012009164209200_bib22","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2026012009164209200_bib23","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/bloodadvances.2024014488","article-title":"Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells","volume":"9","author":"Sdayoor","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"2026012009164209200_bib24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.clml.2025.01.019","article-title":"Role of pulmonary function tests to predict complications after chimeric antigen receptor T-cell therapy","volume":"25","author":"Walder","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/217\/2497020\/blooda_adv-2024-015599-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/217\/2497020\/blooda_adv-2024-015599-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:18:18Z","timestamp":1768918698000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/1\/217\/546726\/New-comorbidity-index-associated-with-survival"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015599","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,13]]},"published":{"date-parts":[[2026,1,5]]}}}